Vest Financial LLC Increases Stake in LeMaitre Vascular, Inc. $LMAT

Vest Financial LLC increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 60.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 56,279 shares of the medical instruments supplier’s stock after acquiring an additional 21,102 shares during the period. Vest Financial LLC’s holdings in LeMaitre Vascular were worth $4,925,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. First Trust Advisors LP raised its stake in LeMaitre Vascular by 52.7% during the second quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock worth $50,829,000 after purchasing an additional 211,280 shares during the period. SG Americas Securities LLC purchased a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at $1,101,000. Envestnet Asset Management Inc. increased its holdings in shares of LeMaitre Vascular by 6.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 304,556 shares of the medical instruments supplier’s stock worth $25,293,000 after buying an additional 19,447 shares during the last quarter. Congress Asset Management Co. raised its position in shares of LeMaitre Vascular by 4.6% in the 2nd quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier’s stock worth $55,973,000 after buying an additional 29,553 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new position in LeMaitre Vascular in the second quarter valued at $892,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Up 1.4%

NASDAQ LMAT opened at $86.99 on Thursday. The stock has a market cap of $1.97 billion, a PE ratio of 37.50, a P/E/G ratio of 1.90 and a beta of 0.68. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $105.55. The business has a 50 day moving average price of $84.51 and a two-hundred day moving average price of $87.45. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.05. The company had revenue of $61.05 million for the quarter, compared to analyst estimates of $62.18 million. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. The business’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. As a group, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 4th. Shareholders of record on Thursday, November 20th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, November 20th. LeMaitre Vascular’s dividend payout ratio is presently 34.48%.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Cantor Fitzgerald reiterated a “neutral” rating and set a $95.00 target price on shares of LeMaitre Vascular in a report on Monday, November 10th. Roth Mkm restated a “buy” rating and issued a $108.00 price target on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Barrington Research reaffirmed an “outperform” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of LeMaitre Vascular in a research report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $100.20.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.